29 results on '"M.A. Molina-Vila"'
Search Results
2. 199P Suppression of mutant Kirsten-RAS (KRAS G12C) non-small cell lung cancer (NSCLC) resistance to KRAS G12C inhibitors by dual inhibition of hepatocyte growth factor receptor (MET) and V-ATPase
3. EP08.02-135 Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)
4. EP08.02-120 MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions
5. EP08.02-032 High Efficiency Multiplex Detection of Molecular Alterations in Supernatants of Pleural Effusion and Cerebrospinal Fluid
6. P65.04 Tracking circRNAs in Lung Adenocarcinoma Samples as Promising Biomarkers for Cancer Detection using the NanoString nCounter®
7. P61.01 Imipramine Blue (IP) plus MET Tyrosine Kinase Inhibitors (TKI) Suppress Lung Adenocarcinoma (LUAD) KRAS Mutation Tumor Growth
8. FP03.04 Selinexor can Inhibit Nuclear Export of HMGB1, a Negative Predictive Marker for Immunotherapy Response
9. FP12.03 SRC-Homology 2 Domain-Containing Phosphatase 2 (SHP2) in Resected Lung Adenocarcinoma (LUAD)
10. P68.05 Human Lung Carcinoma Primary Cultures From Malignant Pleural Effusions as a Tool for Drug Screening and Personalized Therapy
11. P23.02 Digital Multiplexed circRNA Analysis From Plasma-Derived Extracellular Vesicles of Lung Cancer Patients
12. MA03.01 EPICAL Trial. A Phase Ib StudyCombining Anti-Epidermal Growth Factor (EGF) Vaccination With Afatinib in EGFR-Mutant Non-Small Cell Lung Cancer
13. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
14. P60.12 Baseline Tumor Immune Cell Infiltration and Activation can Predict Checkpoint Inhibitor Pneumonitis in Lung Cancer Patients
15. P2.04-22 Programmed Death 1-mRNA Expression Predicts Benefit to Anti-PD1 Monotherapy in a Prospective Cohort of Advanced NSCLC
16. P2.04-79 High Rate of Immune Related Pneumonitis in Lung Cancer Patients Treated with Anti PD-1 Antibodies
17. P1.03-31 BRAF Mutations: Classes I, II and III in NSCLC Patients Included in the SLLIP Trial, Targeted Treatment According to Class
18. P2.03-16 Agreement Between Different Methodologies for Non-Invasive p.T790M and EGFR Sensitizing Mutation Testing
19. 198TiP Afatinib plus EGF pathway targeting immunization (EGF-PTI) as first line therapy for EGFR mutant NSCLC: The EPICAL study
20. P2.01-56 Copy Number Gains (CNGs) of Clinically Relevant Genes in Advanced NSCLC Patients
21. P1.01-56 Increased ROS1 and RET Transcripts in Fusion-Negative NSCLC Patients
22. P2.02-034 PD-L1 Expression Can Be a Prognostic Marker in EGFR Mutant NSCLC Patients Treated with Erlotinib
23. P3.04-13 PD-L1-Gene Expression by nCounter Correlates with PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC)
24. P1.13-01 Anti-EGF Antibodies Increase the Effect of ALK and MEK Inhibitors in ALK and KRAS NSCLC and CRC Cell Lines
25. P2.02-014 Simultaneous Gene Profiling of Advanced NSCLC: Single-Molecule Quantification of DNA and RNA by nCounter3D™ Technology
26. P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC
27. P1.01-075 Simultaneous Multiplex Profiling of Gene Fusions, METe14 Mutations and Immune Genes in Advanced NSCLC by NCounter Technology
28. P1.07-015 Interferon-Gamma (INFG) as a Biomarker to Guide Immune Checkpoint Blockade (ICB) in Cancer Therapy
29. 149P: The role of CTCs and cfDNA for diagnosis and monitoring of EGFR mutations in advanced NSCLC patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.